Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ONC206
JZP3507 · 4 trials · 33 indications
ORR is the best response of confirmed complete response (CR), partial response (PR), or minor response (MR) during the study, as per RANO criteria
ORR defined as the number of participants with a confirmed complete response (CR) or partial response during the study, as per RECIST v1.1.
A DLT is defined as a treatment-related adverse event (AE) or abnormal laboratory value that occurs in the first cycle of treatment (Cycle 1 for Arm A and D; Cycle 0 for Arm B and C), meets criteria for DLT as outlined below and is assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications, and is judged by the investigator to be related to ONC206 as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0).
The Bayesian optimal interval (BOIN) design will be used to find the MTD within each arm. MTD is selected based on isotonic regression and this computation is implemented by the shiny app "BOIN" available at http://www.trialdesign.org. Specifically, select as the MTD the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate. If there are ties, select the higher dose level when the isotonic estimate is lower than the target toxicity rate and select the lower dose level when the isotonic estimate is greater than or equal to the target toxicity rate.
MTD was determined by testing increasing doses up to 200 mg twice daily for 3 successive days a week. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in \>33% of participants. DLTs will be assessed in the first course of each cohort (28 days), and refer to a study drug-related or possibly related event that meets 1 of the following criteria defined in the subsequent Primary Outcome Measure using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE 5.0).
DLTs will be assessed in the first course of each cohort (28 days), and refer to a study drug-related or possibly related event that meets 1 of the following criteria using NCI CTCAE 5.0: * Grade 3 or higher non-hematologic toxicity. * Grade 4 hematologic toxicity (ANC \<0.5 × 109/L and platelet count \<25 × 109/L). Lymphopenia is not considered a DLT. A confirmed DLT requires 2 consecutive measurements separated by 48 hours. * Grade 3 neutropenia (absolute neutrophil count \[ANC\] \<1.0 × 109/L) with elevated fever (\>101°F). A confirmed DLT requires 2 consecutive measurements. * Grade 3 thrombocytopenia with clinically significant bleeding. * Inability to receive the scheduled Cycle 2, Day 1 dose of study drug within 14 days due to study drug-related toxicity persisting from Cycle 1 or study drug-related toxicity newly encountered on Day 1 of Cycle 2.
| Arm | Type | Description |
|---|---|---|
| JZP3507 (ONC206) | EXPERIMENTAL | - |
| Stage 1 Participants | EXPERIMENTAL | 150 mg ONC206 BID TIW |
| Stage 2: Dose 1 | EXPERIMENTAL | Participants receiving ONC206 at dose (To be Determined \[TBD\] post stage 1). |
| Stage 2: Dose 2 | EXPERIMENTAL | Participants receiving ONC206 at dose (TBD post stage 1). |
| Arm A: ONC206 for participants with diffuse midline gliomas + prior therapy | EXPERIMENTAL | Participants receive ONC206 orally (PO) up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. In case the participant receives clinical benefit from the treatment, treatment can proceed up to 24 months. |
| Arm B: ONC206 + radiation therapy for newly diagnosed participants | EXPERIMENTAL | Participants undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. In case the participant receives clinical benefit from the treatment, treatment can proceed up to 24 months. |
| Arm C: ONC206 + radiation therapy, DMGs with evidence of first progression but previously untreated | EXPERIMENTAL | Participants undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. In case the participant receives clinical benefit from the treatment, treatment can proceed up to 24 months. |
| Arm D: ONC206 Therapy, Primary malignant CNS tumors with progression | EXPERIMENTAL | Participants receive ONC206 PO once a day (QD) up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity. In case the participant receives clinical benefit from the treatment, treatment can proceed up to 24 months. |
| ONC206 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JZP3507 | DRUG | Participants will receive oral JZP3507 monotherapy twice daily, on 3 consecutive days per week in 28-day cycles. |
| ONC206 | DRUG | 150 mg BID TIW |
| ONC206: Dose 1 | DRUG | - |
| ONC206: Dose 2 | DRUG | - |
| Standard of Care Radiation Therapy | RADIATION | Undergo RT |
| Optional Proton (1H) MR spectroscopy (MRS) | PROCEDURE | Optional imaging procedure |
Key Inclusion Criteria: Age 1. Is ≥ 18 years of age at the time of signing the informed consent. Type of Participant and Disease Characteristics 2. Has histologically confirmed Grade 2 or 3 meningioma. 3. Has failed, is not a candidate for, or has declined standard of care treatment for mening...
JZP3507 is an investigational small molecule being studied for the treatment of recurrent Grade 2 or 3 meningioma. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated in a single-arm, open-label trial enrolling 30 adult patients in the United States.
JZP3507 targets ClpP and DRD2. ClpP is a mitochondrial protease involved in protein quality control, while DRD2 is a dopamine receptor. By modulating these targets, the drug is being investigated for its potential antitumor activity in recurrent meningioma. The specific mechanism of action in this context is under clinical evaluation.
JZP3507 is being developed by Jazz Pharmaceuticals plc, a biopharmaceutical company traded on NASDAQ under the ticker JAZZ. The company is conducting a Phase 2 clinical trial of JZP3507 in patients with recurrent Grade 2 or 3 meningioma.
JZP3507 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 2 study is actively recruiting participants with recurrent Grade 2 or 3 meningioma, with a planned enrollment of 30 patients.
JZP3507 is being studied in a single active Phase 2 clinical trial with the identifier NCT07533942. The trial, titled "A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma," is recruiting 30 adult patients in the United States. The study is open-label and uncontrolled.
Yes, JZP3507 is also known as ONC206. The ongoing Phase 2 clinical trial NCT07533942 explicitly refers to the drug as JZP3507 (ONC206) in its title, confirming that these names refer to the same investigational compound being developed by Jazz Pharmaceuticals.